留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

CYP3A酶内源性标志物的研究进展

朱桑,  张凤,  高守红,  王志鹏,  陈万生,  陶霞

downloadPDF
文章导航 > 药学实践与服务  > 2016 >  34(5): 385-388,402
朱桑, 张凤, 高守红, 王志鹏, 陈万生, 陶霞. CYP3A酶内源性标志物的研究进展[J]. 药学实践与服务, 2016, 34(5): 385-388,402. doi: 10.3969/j.issn.1006-0111.2016.05.001
引用本文: 朱桑, 张凤, 高守红, 王志鹏, 陈万生, 陶霞. CYP3A酶内源性标志物的研究进展[J]. 药学实践与服务, 2016, 34(5): 385-388,402. doi: 10.3969/j.issn.1006-0111.2016.05.001
shu
ZHU Sang, ZHANG Feng, GAO Shouhong, WANG Zhipeng, CHEN Wangsheng, TAO Xia. Research progress of in vivo biomarkers for CYP3A enzyme[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(5): 385-388,402. doi: 10.3969/j.issn.1006-0111.2016.05.001
Citation: ZHU Sang, ZHANG Feng, GAO Shouhong, WANG Zhipeng, CHEN Wangsheng, TAO Xia. Research progress of in vivo biomarkers for CYP3A enzyme[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(5): 385-388,402. doi: 10.3969/j.issn.1006-0111.2016.05.001
shu

CYP3A酶内源性标志物的研究进展

doi: 10.3969/j.issn.1006-0111.2016.05.001

  • 上海长征医院药材科, 上海 200003

基金项目: 国家自然科学基金面上项目（81573793）

Research progress of in vivo biomarkers for CYP3A enzyme

  • Department of Pharmacy, Changzheng Hospital, Shanghai 200003, China

  • 摘要: CYP3A酶主要分布于人体肝脏和小肠，广泛参与各种药物代谢。该酶在介导药物代谢的同时也会受底物影响，其活性被诱导或抑制，从而影响其他经由CYP3A酶代谢的药物体内过程。目前可以通过体外探针药物和内源性生物标志物评价CYP3A酶活性，前者需要口服探针药物，后者只需检测内源性标志物如4β-羟基胆固醇和6β-羟基氢化可的松。文献报道，研究CYP3A酶活性除了有助于阐明不同个体的药物代谢差异，还可以提示药物相互作用情况下合用药物的剂量调整，预测药物疗效和毒性反应，为个体化用药提供理论指导，评估新药潜在的药物相互作用，降低新药上市风险。笔者对上述2种常用的内源性标志物的相关研究和临床应用进行综述。
    Abstract: Human cytochrome P450 (CYP) 3A, which is widely involved in the various drug metabolism, is most abundant in liver and intestine. The activity of CYP3A enzyme may be induced or inhibited in the process of drug metabolisms, and affect the metabolism of other CYP3A substrates and modulators vice versa. At present, in vitro probe drugs and in vivo biomarkers are both available to evaluate the activity of CYP3A enzyme. The former requires oral probe drugs, the latter does not need for those drugs and just allows laboratory technicians to detect endogenous substrates, such as 4β-hydroxycholesterol and 6β-hydroxycortisol. As reported, studies on CYP3A help to explain the inter-individually variability in drug metabolism, to indicate dose adjustments in combination regimens when drug interactions exist, to predict drug efficacy and toxicity reaction for providing theoretical guidance for individualized medication, and to reduce market risk of new drugs for the potential drug interactions. We summarized these two kinds of endogenous biomarkers and their clinical application in this review.
  • [1] Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients[J]. J Pharmacol Exp Ther, 1994, 271(1): 549-556.
    [2] 韩现芹, 李 健, 王 群. 用药动学方法研究甘草和连翘对牙鲆CYP3A活性的影响[C]. 第十二届中国科协年会论文集. 福州,2010: 1-7.
    [3] De wildt SN, Berns MJ, Van den anker JN. 13C-erythromycin breath test as a noninvasive measure of CYP3A activity in newborn infants: a pilot study[J]. Ther Drug Monit, 2007, 29(2): 225-230.
    [4] Mirghani RA, Sayi J, Aklillu E, et al. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population[J]. Pharmacogenet Genomics, 2006, 16(9): 637-645.
    [5] Shoun H, Fushinobu S. Physiological function, reaction mechanism, and structure of cytochrone P450nor[J]. Seikagaku, 2008, 80(6): 560-568.
    [6] Burk O, Wojnowski L. Cytochrome P450 3A and their regulation[J]. Naunyn Schmiedebergs Arch Pharmacol, 2004, 369(1): 105-124.
    [7] Paine MF, Hart HL, Ludington SS, et al. The human intestinal cytochrome P450 "pie"[J]. Drug Metab Dispos, 2006, 34(5): 880-886.
    [8] Akiyoshi T, Saito T, Murase S, et al. Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants[J]. Drug Metab Dispos, 2011, 39(4): 724-728.
    [9] Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism[J]. Pharmacogenetics, 2001, 11(9): 773-779.
    [10] Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression[J]. Nat Genet, 2001, 27(4): 383-391.
    [11] Lin YS, Dowling AL, Quigley SD, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism[J]. Mol Pharmacol, 2002, 62(1): 162-172.
    [12] Bodin K, Andersson U, Rystedt E, et al. Metabolism of 4 beta -hydroxycholesterol in humans[J]. J Biol Chem, 2002, 277(35): 31534-31540.
    [13] Hukkanen J, Puurunen J, Hyotylainen T, et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity[J]. Br J Clin Pharmacol, 2015, 80(3): 473-479.
    [14] Yang Z, Rodrigues AD. Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric?[J]. J Clin Pharmacol, 2010, 50(11): 1330-1338.
    [15] Diczfalusy U, Nylen H, Elander P, et al. 4beta-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans[J]. Br J Clin Pharmacol, 2011, 71(2): 183-189.
    [16] Goodenough AK, Onorato JM, Ouyang Z, et al. Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis[J]. Chem Res Toxicol, 2011, 24(9): 1575-1585.
    [17] Dutreix C, Lorenzo S, Wang Y. Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin[J]. Eur J Clin Pharmacol, 2014, 70(8): 915-920.
    [18] Bjorkhem-bergman L, Backstrom T, Nylen H, et al. Comparison of endogenous 4beta-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin[J]. Drug Metab Dispos, 2013, 41(8): 1488-1493.
    [19] Leil TA, Kasichayanula S, Boulton DW, et al. Evaluation of 4beta-Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism-Based Pharmacometric Model[J]. CPT Pharmacometrics Syst Pharmacol, 2014, 25(3):e120.
    [20] Kasichayanula S, Boulton DW, Luo WL, et al. Validation of 4beta-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects[J]. Br J Clin Pharmacol, 2014, 78(5): 1122-1134.
    [21] Diczfalusy U, Kanebratt KP, Bredberg E, et al. 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin[J]. Br J Clin Pharmacol, 2009, 67(1): 38-43.
    [22] Furuta T, Suzuki A, Mori C, et al. Evidence for the validity of cortisol 6 beta-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans[J]. Drug Metab Dispos, 2003, 31(11): 1283-1287.
    [23] Shibata S, Takahashi H, Ono N, et al. Longitudinal monitoring of CYP3A activity in patients receiving 3 cycles of itraconazole pulse therapy for onychomycosis[J]. J Clin Pharm Ther, 2014, 39(2): 181-185.
    [24] Hu ZY, Zhao YS, Wu D, et al. Endogenous cortisol 6 beta-hydroxylation clearance is not an accurate probe for overall cytochrome P450 3A phenotyping in humans[J]. Clin Chim Acta, 2009, 408(1-2): 92-97.[25] Peng CC, Templeton I, Thummel KE, et al. Evaluation of 6beta-hydroxycortisol, 6beta-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo[J]. Clin Pharmacol Ther, 2011, 89(6): 888-895.
    [25] Marde Arrhen Y, Nylen H, Lovgren-sandblom A, et al. A comparison of 4beta-hydroxycholesterol : cholesterol and 6beta-hydroxycortisol : cortisol as markers of CYP3A4 induction[J]. Br J Clin Pharmacol, 2013, 75(6): 1536-1540.
    [26] Ohno M, Yamaguchi I, Ito T, et al. Circadian variation of the urinary 6beta-hydroxycortisol to cortisol ratio that would reflect hepatic CYP3A activity[J]. Eur J Clin Pharmacol, 2000, 55(11-12): 861-865.
    [27] Fleishaker JC, Pearson PG, Wienkers LC, et al. Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability[J]. J Pharmacol Exp Ther, 1996, 277(2): 991-998.
    [28] Shibasaki H, Hosoda K, Goto M, et al. Intraindividual and interindividual variabilities in endogenous cortisol 6beta-hydroxylation clearance as an index for in vivo CYP3A phenotyping in humans[J]. Drug Metab Dispos, 2013, 41(2): 475-479.
    [29] Luo X, Zheng L, Cai N, et al. Evaluation of 6beta-hydroxycortisol and 6beta-hydroxycortisone as biomarkers for cytochrome P450 3A activity: insight into their predictive value for estimating oral immunosuppressant metabolism[J]. J Pharm Sci, 2015, 104(10): 3578-3586.
    [30] Diczfalusy U, Miura J, Roh HK, et al. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians[J]. Pharmacogenet Genomics, 2008, 18(3): 201-208.
    [31] Tremblay-franco M, Zerbinati C, Pacelli A, et al. Effect of obesity and metabolic syndrome on plasma oxysterols and fatty acids in human[J]. Steroids, 2015, 99(Pt B): 287-292.
    [32] Mannheimer B, Wagner H, Ostenson CG, et al. No impact of vitamin D on the CYP3A biomarker 4beta-hydroxycholesterol in patients with abnormal glucose regulation[J]. PLoS One, 2015, 10(4): e0121984.
    [33] Woolsey SJ, Beaton MD, Choi YH, et al. Relationships between endogenous plasma biomarkers of constitutive CYP3A activity with single time-point oral midazolam microdose phenotype in healthy subjects[J]. Basic Clin Pharmacol Toxicol, 2016,118(4):284-291.
    [34] Woolsey SJ, Mansell SE, Kim RB, et al. CYP3A activity and expression in nonalcoholic fatty liver disease[J]. Drug Metab Dispos, 2015, 43(10): 1484-1490.
    [35] Suzuki Y, Itoh H, Sato F, et al. Significant increase in plasma 4beta-hydroxycholesterol concentration in patients after kidney transplantation[J]. J Lipid Res, 2013, 54(9): 2568-2572.
    [36] Suzuki Y, Itoh H, Fujioka T, et al. Association of plasma concentration of 4beta-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients[J]. Drug Metab Dispos, 2014, 42(1): 105-110.
    [37] Muro EP, Fillekes Q, Kisanga ER, et al. Intrapartum single-dose carbamazepine reduces nevirapine levels faster and may decrease resistance after a single dose of nevirapine for perinatal HIV prevention[J]. J Acquir Immune Defic Syndr (1999), 2012, 59(3): 266-273.
    [38] Baranyai D, Muro E, Godtel-armbrust U, et al. Reduction of nevirapine-driven HIV mutations by carbamazepine is modulated by CYP3A activity[J]. J Antimicrob Chemother, 2014, 69(7): 1933-1937.
    [39] 卜书红, 张 健, 陆晓彤, 等. 儿童癫痫患者CYP酶活性与血清卡马西平浓度和临床疗效的相关性分析[J]. 医药导报, 2010, 29(4): 430-432.
    [40] 张 健, 唐跃年, 刘海涛, 等. 急性淋巴细胞性白血病患儿化疗前后CYP3A酶活性研究[J]. 中国药师, 2007, 10(2): 110-112.
    [41] Rouits E, Charasson V, Petain A, et al. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients[J]. Br J Cancer, 2008, 99(8): 1239-1245.
  • [1] 赖立勇, 夏天爽, 徐圣焱, 蒋益萍, 岳小强, 辛海量.  中药青蒿抗氧化活性的谱效关系研究 . 药学实践与服务, 2024, 42(5): 203-210, 216. doi: 10.12206/j.issn.2097-2024.202211012
    [2] 张广雨, 杜晶, 刘梦珍, 朱丹妮, 闫慧, 刘冲.  新斯的明与山莨菪碱联合应用对肺型氧中毒的保护作用及其机制的研究 . 药学实践与服务, 2024, 42(10): 433-438, 444. doi: 10.12206/j.issn.2097-2024.202310049
    [3] 陈炳辰, 王思真, 郭贝贝, 杨峰.  紫杉醇棕榈酸酯的合成及其脂质体的制备与处方研究 . 药学实践与服务, 2024, 42(9): 379-384, 410. doi: 10.12206/j.issn.2097-2024.202404062
    [4] 毛泽玲, 文波.  大黄的HPLC指纹图谱及禁用农药的残留研究 . 药学实践与服务, 2024, 42(7): 297-304, 314. doi: 10.12206/j.issn.2097-2024.202310057
    [5] 宋泽成, 陈林林, 鲁仁义, 刘梦肖, 王彦.  脓毒症治疗的研究进展 . 药学实践与服务, 2024, 42(11): 457-460, 502. doi: 10.12206/j.issn.2097-2024.202405059
    [6] 张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英.  二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
    [7] 石晓萍, 吕迁洲, 李晓宇, 许青.  泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202401050
    [8] 杨嘉宁, 赵一颖, 肖伟.  七味脂肝方对非酒精性脂肪性肝炎动物模型的药效学评价 . 药学实践与服务, 2024, 42(9): 389-398. doi: 10.12206/j.issn.2097-2024.202404096
    [9] 迟文雅, 袁艳, 李伟林, 吴茼妤, 俞媛.  负载骨髓间充质干细胞/白藜芦醇脂质体的水凝胶支架用于创伤性脑损伤治疗 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202406034
    [10] 戴菲菲, 傅翔, 陈琼年, 俞苏纯.  上海某二级医院革兰阴性菌流行特征的回顾性分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202305005
    [11] 唐淑慧, 凤美娟, 薛智霞, 鲁桂华.  帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
    [12] 刘丽艳, 余小翠, 孙传铎.  纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
    [13] 孙丹倪, 黄勇, 张嘉宝, 王培.  代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
    [14] 王耀振, 徐灿, 吕顺莉, 田泾, 张东炜.  钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
    [15] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [16] 冯志惠, 邓仪卿, 叶冰, 安培, 张宏, 张海军.  雀梅藤石油醚提取物诱导三阴性乳腺癌细胞凋亡的实验研究 . 药学实践与服务, 2024, 42(6): 253-259. doi: 10.12206/j.issn.2097-2024.202311055
    [17] 景凯, 杨慈荣, 张圳, 臧艺蓓, 刘霞.  黄芪甲苷衍生物治疗慢性心力衰竭小鼠的药效评价及作用机制研究 . 药学实践与服务, 2024, 42(5): 190-197. doi: 10.12206/j.issn.2097-2024.202310004
    [18] 刘汝雄, 杨万镇, 涂杰, 盛春泉.  铁死亡调控蛋白GPX4的小分子抑制剂研究进展 . 药学实践与服务, 2024, 42(9): 375-378. doi: 10.12206/j.issn.2097-2024.202312075
    [19] 李丹, 戴贤春, 王芳珍, 陈奕含, 杨萍, 刘继勇.  HPLC-MS/MS测定当归六黄汤中4种不同成分的含量 . 药学实践与服务, 2024, 42(6): 248-252, 266. doi: 10.12206/j.issn.2097-2024.202305007
    [20] 桂明珠, 李静, 李志玲.  儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  4107
  • HTML全文浏览量:  492
  • PDF下载量:  540
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-12-30
  • 修回日期:  2016-03-15

CYP3A酶内源性标志物的研究进展

doi: 10.3969/j.issn.1006-0111.2016.05.001
  • 上海长征医院药材科, 上海 200003
    • 基金项目:  国家自然科学基金面上项目（81573793）
  • 收稿日期: 2015-12-30
  • 修回日期: 2016-03-15

摘要: CYP3A酶主要分布于人体肝脏和小肠，广泛参与各种药物代谢。该酶在介导药物代谢的同时也会受底物影响，其活性被诱导或抑制，从而影响其他经由CYP3A酶代谢的药物体内过程。目前可以通过体外探针药物和内源性生物标志物评价CYP3A酶活性，前者需要口服探针药物，后者只需检测内源性标志物如4β-羟基胆固醇和6β-羟基氢化可的松。文献报道，研究CYP3A酶活性除了有助于阐明不同个体的药物代谢差异，还可以提示药物相互作用情况下合用药物的剂量调整，预测药物疗效和毒性反应，为个体化用药提供理论指导，评估新药潜在的药物相互作用，降低新药上市风险。笔者对上述2种常用的内源性标志物的相关研究和临床应用进行综述。

English Abstract

朱桑, 张凤, 高守红, 王志鹏, 陈万生, 陶霞. CYP3A酶内源性标志物的研究进展[J]. 药学实践与服务, 2016, 34(5): 385-388,402. doi: 10.3969/j.issn.1006-0111.2016.05.001
引用本文: 朱桑, 张凤, 高守红, 王志鹏, 陈万生, 陶霞. CYP3A酶内源性标志物的研究进展[J]. 药学实践与服务, 2016, 34(5): 385-388,402. doi: 10.3969/j.issn.1006-0111.2016.05.001
shu
ZHU Sang, ZHANG Feng, GAO Shouhong, WANG Zhipeng, CHEN Wangsheng, TAO Xia. Research progress of in vivo biomarkers for CYP3A enzyme[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(5): 385-388,402. doi: 10.3969/j.issn.1006-0111.2016.05.001
Citation: ZHU Sang, ZHANG Feng, GAO Shouhong, WANG Zhipeng, CHEN Wangsheng, TAO Xia. Research progress of in vivo biomarkers for CYP3A enzyme[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(5): 385-388,402. doi: 10.3969/j.issn.1006-0111.2016.05.001
shu

    全文HTML

参考文献 (41)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: [email protected]

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计